CD4 and neoplasm: These results have a dual value, as they challenge the widely accepted dogma that DC are the only cell type performing in vivo priming of MHC-II-restricted CD4+ Th cells [13,57] and, at the same time, offer the opportunity to investigate the repertoire of potential tumor antigens expressed by these modified tumor cells for novel vaccination strategies [29,30] (Figure 2).